FinalDose

Competitive Intelligence & Product Roadmap

Programmable DNA drug platform for genetically defined cancer targets.

Company Overview

FinalDose is a preclinical biotech that builds programmable DNA-targeting drugs that kill cells when they recognize diseased genetic code. Serving future oncology drug buyers: pharma partners and clinical researchers.

Latest Intel

Zeitgeist tracks private signals to determine where the company is heading strategically.

New Intel: FinalDose is centering the company on a programmable DNA-sensing kill switch for cancer. That points to a platform biotech bet where pharma value comes from repeatable target programming, not one disclosed lead asset.

What They're Building

The company's public product roadmap & what they're committed to building.

Programmable DNA Drug

FinalDose is building a molecular platform that can be reprogrammed with diseased genetic code rather than rediscovered for each protein target.

Genome Scanning Mechanism

The company says its molecule scans cellular DNA for a hardcoded target sequence before changing structure on recognition.

Target-Triggered Cell Killing

The stated therapeutic action is a kill switch that destroys only cells carrying the selected genetic sequence.

Oncology First

FinalDose is starting with cancer, including targets described publicly as MYC, TP53, and APC.

Founder and Key Execs

Jeff Liu

CEO & Co-Founder (Oxford PhD in Oncology, previously co-founded Vivid Dx)

Li-Yao Huang

Founder & CSO (Oxford DPhil in Biochemistry, CRISPR screening and BRCA1/PARP inhibitor resistance work)

Steven Lin

Founder & CTO (Oxford PhD in Computational Biology, machine learning and genetic drug-resistance research)

Founder Force Multiplier

The founding team combines oncology, biochemistry, CRISPR screening, and computational biology. That mix fits a company where the hard problem spans target biology, molecular design, and experimental validation.

Funding History

2025 | Founded and incorporated in the UK
2026 | Joined YCombinator Spring 2026, with no disclosed round beyond YC found

Competitors

Insufficient data

FinalDose

's Moat:

The candidate moat is proprietary wet-lab data linking guide sequence, DNA recognition, cell killing, and off-target behavior; it is not yet proven publicly.

How They're Leveraging AI

Guide sequence design for DNA-targeted cell killing

FinalDose likely applies ML upstream to choose diseased DNA sequences and design programmable guides for its cancer-killing molecule. The user-facing outcome is a drug platform where changing the genetic code input could create a new therapeutic program.

Off-target toxicity prediction for programmable therapeutics

FinalDose likely needs predictive models to estimate whether a programmed molecule will hit healthy DNA sequences or trigger unwanted cell death. This would sit behind candidate selection, not as a visible software product.

AI Use Overview:

FinalDose likely uses ML for target and guide design, but public evidence does not yet show a differentiated model or proprietary training corpus.

Bio, Drug Discovery, and Medical Imaging

10xScience

Turns weeks of manual protein analysis into minutes for drug development teams.

CellType

Simulates human biology with AI to predict drug effects and run virtual trials.

Google CEO Sundar Pichai highlighted their C2S-Scale 27B model for generating a novel cancer hypothesis that was later validated experimentally. CellType simulates human biology to predict drug effects using foundation models presented at ICML 2024, with all deals coming inbound from top-10 pharma. Yale professor turned down Google to build it.

Ditto Biosciences

Mines parasite genomes to discover protein therapeutics for autoimmune diseases.

Parasites evolved to suppress human immune responses over millions of years. Ditto mines their genomes for immunomodulatory proteins, and over 98% of those proteins remain uncharacterized. Three PhDs from Harvard, Berkeley, and UCSF with 40+ years of combined expertise in host-parasite biology.

Mango Medical

Automates surgical planning for orthopedic procedures from CT scans using agentic AI.

Surgical planning for shoulder replacements takes hours of manual CT scan interpretation. Mango automates it in seconds via API, already past $500K ARR before demo day, with an 8-figure LOI from a leading orthopedic company. Only company in YC W26 pursuing FDA 510(k) clearance.

Back To All Companies >